Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
According to the WHO’s World Mental Health Report, approximately one billion people are living with a mental disorder and nearly three hundred million adults have depression worldwide [1,2]. The ubiquity of mental health disorders results in an estimated 12 billion workdays lost annually due to depression and anxiety alone, and results in costs to the global economy of nearly
“Axsome shares the World Health Organization’s vision of a world in which mental health is valued, promoted and protected. We are pleased to add our voice to raise awareness of mental health on this important day,” said
A variety of mental well-being resources from the
As part of Axsome’s commitment to depression education, resources and tools are available at www.talkdepressettling.com to help support those affected by depression.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of our Sunosi® product and the success of our efforts to obtain any additional indication(s) with respect to Sunosi; the commercial success of our Auvelity™ product and the success of our efforts to obtain any additional indication(s) with respect to AXS-05, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain
Chief Operating Officer
- World mental health report: transforming mental health for all.
Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA3.0 IGO. World Health Organization. (2021, September 13). Depression. World Health Organization Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/depression World Health Organization. (2022, September 28). Joint News Release. https://www.who.int/news/item/28-09-2022-who-and-ilo-call-for-new-measures-to-tackle-mental-health-issues-at-work
Source: Axsome Therapeutics, Inc.